VSTM Overview
Upcoming Projects (VSTM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (VSTM)
-
Reviewing Verastem's recent Phase I/II data investigating their kinase inhibitor, avutometinib, for the treatment of metastatic pancreatic cancer
Ticker: VSTM
Executed On: Jul 18, 2024 at 04:00 PM EDT -
A Third Look: Discussing avutometinib from Verastem and its phase 1/2 trials RAMP 201 (Part A and B) & 203 trials (combo with KRAS for LGSOC or low grade serous ovarian cancer)
Ticker: VSTM
Executed On: Jun 11, 2024 at 08:30 AM EDT -
A Second Look: Discussing avutometinib from Verastem and its phase 1/2 trials RAMP 201 (Part A and B) & 203 trials (combo with KRAS for LGSOC or low grade serous ovarian cancer)
Ticker: VSTM
Executed On: May 30, 2024 at 01:00 PM EDT -
Discussing avutometinib from Verastem and its phase 1/2 trials RAMP 201 (Part A and B) & 203 trials (combo with KRAS for LGSOC or low grade serous ovarian cancer)
Ticker: VSTM
Executed On: May 14, 2024 at 11:00 AM EDT -
Discussing Low-Grade Serous Ovarian Carcinoma (LGSOC) with a specific focus on VS-6766 and trametinib
Tickers: VSTM, NVS
Executed On: Apr 08, 2022 at 11:00 AM EDT
Upcoming & Overdue Catalysts (VSTM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (VSTM)
-
NDA Filing for Duvelisib Projected Q1 of 2018
Tickers: VSTM, INFI
Occurred on: Feb 07, 2018 -
Phase 1/2 initial data of Duvelisib - CONTEMPO trial for treatment-naive patients with follicular lymphoma due 2H 2016 -Study Withdrawn
Tickers: VSTM, INFI
Occurred on: Jun 29, 2016
Strategic Initiatives (VSTM)
-
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Tickers: MRK, PFE, VSTM
Announcement Date: Mar 03, 2016
